The PPAR Journey: What Can We Expect in the Future?

Targets of Glucose-Lowering Drugs

PPAR-a and PPAR-g Agonists: Target Systems

Effects of Fibrates on Cardiovascular Events: A Systematic Review and Meta-Analysis

CV Events With PPAR-g Agonists

Expected Targets for Dual PPAR-a/g Agonists

Dual PPAR a/g Agonists

GALLANT 8: Effect of Tesaglitazar on Top of Metformin vs Metformin Alone on HbA1c

GLAD: Effect of Tesaglitazar vs Pioglitazone on Lipid Measures

Tesaglitazar: Effect on Serum Creatinine and Glomerular Filtration

Dual a/g PPAR Agonist: Effect of Muraglitazar on Metabolic Parameters

Effect of Muraglitazar on CV Outcomes

SYNCHRONY: Effect of Aleglitazar on Cardiometabolic Parameters in T2D

SYNCHRONY: Cardiovascular Safety

SYNCHRONY: Effect of Aleglitazar on Markers of Renal Function

SESTA R: Impact of Supratherapeutic Doses of Aleglitazar on Renal Function in T2D

ALENEPHRO: Objective and Study Design

Summary: PPAR Therapy

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)